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Abstract 
 
Background: The epithelial-mesenchymal transition (EMT) is a key process in 
tumor progression and metastasis and is also associated with drug resistance. 
Thus, controlling EMT status is a research of interest to conquer the malignant 
tumors. 
Materials and methods: A drug repositioning analysis of transcriptomic data 
from a public cell line database identified monensin, a widely used in veterinary 
medicine, as a candidate EMT inhibitor that suppresses the conversion of the 
EMT phenotype. Using TGF-β-induced EMT cell line models, the effects of 
monensin on the EMT status and EMT-mediated drug resistance were assessed. 
Results: TGF-β treatment induced EMT in non-small cell lung cancer (NSCLC) 
cell lines and the EGFR-mutant NSCLC cell lines with TGF-β-induced EMT 
acquired resistance to EGFR-tyrosine kinase inhibitor. The addition of monensin 
effectively suppressed the TGF-β-induced-EMT conversion, and restored the 
growth inhibition and the induction of apoptosis by the EGFR-tyrosine kinase 
inhibitor. 
Conclusion: Our data suggested that combined therapy with monensin might be 




The epithelial-mesenchymal transition (EMT) is a phenotypic conversion of 
epithelial features into mesenchymal features: a decrease in intracellular 
adhesion and cell polarity, and an increase in matrix remodeling and motility. 
These changes confer the tumor metastatic behaviors of cancer cell invasion and 
migration. Several key signaling pathways, including transforming growth factor-
β (TGF-β), Wnt, Notch and Hedgehog, are involved in this process. Of these, 
TGF-β is considered to be a pivotal mediator of the EMT during physiological 
processes [1-3], and TGF-β treatment is a well-established method of inducing 
the EMT in vitro in cell line models [4]. The EMT is also known to be involved in 
resistance to a variety of therapeutic modalities, including chemotherapy with 
cytotoxic drugs or molecularly targeted drugs, as well as radiation therapy in 
diverse cancer types [2, 5]. The mechanism of this EMT-mediated drug resistance 
has been studied for decades; so far, EMT-driven cancer stem cell (CSC)-like 
properties, such as an increase in drug efflux and anti-apoptotic effects, have 
received attention for their pivotal roles in cancer drug resistance [1, 2, 6, 7]. The 
EMT is a promising target for novel therapeutic strategies targeting cancer 
progression and drug resistance; however, this approach is potentially 
challenging because the EMT is intricately regulated by numerous factors, such 
as extracellular matrix components, diverse signal pathways, soluble growth 
factors or cytokines, and microRNAs [1, 2, 8].  
The process of finding new uses outside the scope of the original medical 
indications of existing drugs is known as drug repositioning. This approach 
represents an increasingly promising, cost-effective alternative strategy for 
accelerating the development of treatments for diseases, since previous 
development efforts and preclinical and clinical data, especially safety profiles, 
are usually available [9]. Several drugs have been successfully repositioned for 
new indications, with two of the most notable examples being sildenafil and 
thalidomide [10]. 
In this study, we conducted an in silico drug repositioning analysis of 
transcriptomic data from a cell line database and identified monensin as a 
candidate EMT inhibitor capable of reversing the EMT phenotype. Monensin is a 
polyether ionophore that is widely used as an antibiotic in livestock animals [11]. 
We then assessed the inhibitory effect of monensin on the EMT phenotype and 
its potential to overcome EMT-mediated drug resistance. 
 
Materials and methods 
Bioinformatics analysis 
Comprehensive transcriptomic profiles of 28 NSCLC cell lines were obtained from 
the Cancer Cell Line Encyclopedia (CCLE) database 
(http://www.broadinstitute.org/ccle/). Gene set enrichment analysis (GSEA) was 
performed using GSEA_4.0.1 software and a database of gene sets obtained 
from Molecular Signatures Database v5.0 (https://www.gsea-msigdb.org/gsea/) 
[12]. A Connectivity Map (C-MAP) analysis was performed using the tool 
described by Lamb and colleagues [13]. We selected 164 probes that were 
positively correlated with the expression pattern of mir-200c and an additional 
124 probes that were negatively correlated with the expression pattern of mir-
200c in the CCLE database; we then used the selected probes as queries in 
comparisons with the rank-ordered lists for each drug treatment in the C-MAP 
database. Since C-MAP analysis is only applicable for Affymetrix type probe IDs 
of HG-U133A Gene Chips, we transformed the probe IDs from HG-U133 plus2 
Gene Chips in the CCLE database into HG-U133A based on gene symbol 
comparisons using the GPL96 file from GEO (http://www.ncbi.nlm.nih.gov/geo/). 
As a result, 87 of the 164 positive-correlated probes and 52 of the 124 negative-
correlated probes were used for C-MAP analysis. 
 
Cell culture and reagents 
Two EGFR-mutant NSCLC cell lines: HCC827 (EGFR exon19del E746-A750), 
H1975 (EGFR L858R and T790M), one KRAS mutant NSCLC cell line, A549 
(KRAS G12S) and one pancreatic cancer cell line, PANC-1 (KRAS G12D), were 
used in this study. All cell lines were purchased from the American Type Culture 
Collection (Manassas, VA, USA). These cell lines were cultured in Roswell Park 
Memorial Institute-1640 medium supplemented with 10% fetal bovine serum at 
37 ºC in humidified incubator under 5% CO2 gas. Osimertinib, EGFR-tyrosine 
kinase inhibitor, was purchased from ChemScene (Monmouth Junction, NJ, USA) 
and monensin was purchased from Cayman Chemical (Ann Arbor, MI, USA). 
TGF-β was purchased from Wako (Osaka, Japan). 
 
Cell viability assay 
The sensitivity to each drug was determined by a modified MTS assay. Cells were 
plated at a density of 3,000 cells per well in 96-well plates, and treated with the 
desired concentration of drugs. Cell viability was assayed after 96 hours of 
treatment using CellTiter 96 Aqueous bromide One Solution Reagent (Promega, 
Madison, WI, USA). For measurement of IC50 value, each condition was assayed 
in eight-replicate determinations in three independent experiments. Data was 
analyzed by non-linear regression using Graphpad Prism Ver. 6.0.3 (GraphPad 
Software, San Diego, CA). 
 
Western blotting 
Cells were treated with ethanol (Wako, Osaka, Japan) as a control, 2 ng/mL TGF-
β and 100 nM monensin. The total cell lysate was extracted with lysis buffer, a 
mixture of RIPA buffer, phosphate inhibitor cocktails 2 and 3 (Sigma-Aldrich, St. 
Louis, MO, USA) and complete Mini Protease Inhibitor Cocktail (Roche, 
Switzerland). Western blot analysis was performed by using the following primary 
antibodies: E-cadherin, vimentin, poly ADP-ribose polymerase (PARP), GAPDH 
(Cell Signaling Technology, Danvers, MA, USA) and ZEB1 (Santa Cruz 
Biotechnology, Dallas, TX, USA). The secondary antibody was HRP-conjugated 
anti-mouse or anti-rabbit IgG (Santa Cruz Biotechnology, Dallas, TX, USA). To 
detect specific signals, the membrane was examined using the ECL Prime 
Western Blotting Detection System (GE Healthcare, Amersham, UK) and LAS-
3000 (Fujifilm, Tokyo, Japan). The relative band intensities were quantified using 





Drug repositioning analysis for reversion of EMT signatures. 
 
We previously reported the EMT status in 34 non-small cell lung cancer (NSCLC) 
cell lines [14]. The EMT status was determined based on the protein expressions 
of E-cadherin, vimentin, N-cadherin, ZEB1, and ZEB2 evaluated using western 
blotting analyses and the expressions of miR-200s, which are microRNAs known 
to be key players in the regulation of EMT features, evaluated using qPCR. For 
this study, we extracted 28 cell lines for which comprehensive gene expression 
data were available in the CCLE database (http://www.broadinstitute.org/ccle/), 
and we stratified them into two groups: 12 cell lines with an epithelial-like 
phenotype, and 16 cell lines with a mesenchymal-like phenotype (Fig. 1A). We 
then performed GSEA to investigate the validity of this classification, and we 
confirmed that the Epithelial_Mesenchymal_Transition gene set was significantly 
enriched in the mesenchymal-like phenotype group (Fig.1B). Next, to identify 
reagents with the potential to reverse the EMT, we conducted C-MAP analysis. 
C-MAP is a widely used computational method for drug repositioning, containing 
a large transcriptomic compendium of drug-treated human cancer cells [13, 15]. 
By testing user-provided gene lists (query list) against a large number of 
transcriptional profiles, potentially bioactive small molecules can be screened [13, 
15]. Based on the transcriptional profiles of 28 NSCLC cell lines, we selected 87 
“epithelial-like” probes with positive correlations to mir-200c expression, including 
CDH1, as well as 52 “mesenchymal-like” probes with negative correlations to mir-
200c expression, including ZEB1 (Supplementary Table 1). We then used these 
probes as a query list for comparisons with the rank-ordered lists for each drug 
treatment in the C-MAP database. We identified multiple Food and Drug 
Administration (FDA)-approved drugs with a significantly biased appearance of 
the query genes toward an epithelial-like feature (Table 1). The first ranked drug, 
thioridazine, is an antipsychotic drug; however, it was withdrawn from the market 
worldwide in 2005 because of its effect on the central nervous system and 
cardiotoxicity. We then focused on the second-ranked drug monensin, which is a 
polyether ionophore that is currently used as an antibiotic in livestock animals. 
The results of Kolmogorov-Smirnov scanning for monensin are shown in Fig. 1C. 
Furthermore, all six independent experiments using different cell lines with 
different doses showed a positive effect on epithelial-like features (Fig. 1D). In 




TGF-β stimulation facilitates EMT in cancer cells, leading to resistance to 
molecularly targeted therapy 
 
TGF-β is a critical effector facilitating EMT through the modulation of Smad 
signaling, and TGF-β treatment is a well-established method for inducing the EMT 
in vitro [4]. To assess the suppressive effect of monensin on the switch to EMT, 
we used TGF-β-induced EMT models in vitro. First, we examined the facilitating 
EMT effect of TGF-β in three NSCLC cell lines (A549, HCC827 and H1975) and 
one pancreatic cancer cell line (PANC-1). As expected, following TGF-β 
stimulation for 72 hours, these cells showed an up-regulation of the mesenchymal 
markers vimentin and ZEB1 and/or a down-regulation of the epithelial marker E-
cadherin (Fig. 2A). Morphological changes were also observed; some of the TGF-
β-treated cells transformed to a spindle cell shape (Fig. 2B), indicating that these 
cell lines acquired an EMT phenotype as a result of TGF-β treatment. Next, to 
determine the drug sensitivities of TGF-β-induced EMT cell models, we compared 
the sensitivity to osimertinib, an EGFR tyrosine kinase inhibitor, in the EGFR-
mutant NSCLC cell lines HCC827 and H1975 in the presence or absence of TGF-
β. In the absence of TGF-β, cell proliferation was effectively suppressed in both 
cell lines, whereas cells with TGF-β-induced EMT in the presence of TGF-β were 
less sensitive to osimertinib (Fig. 2C). These results show that TGF-β stimulation 
induced EMT and that TGF-β-induced EMT NSCLC cell models are useful for 
investigating EMT-mediated drug resistance. 
 
Combined therapy with monensin as a therapeutic strategy for preventing 
EMT-mediated resistance 
 
To validate the in silico findings of monensin as a candidate anti-EMT drug, we 
tested the inhibitory effect of monensin on the EMT using TGF-β-induced EMT 
cell models. Cells were cultured in the presence or absence of monensin and/or 
TGF-β for 72 hours, and the protein expressions of EMT markers were then 
analyzed. As shown in Fig. 3A, the addition of monensin suppressed the up-
regulation of vimentin by TGF-β stimulation in HCC827 and A549 cells; the up-
regulation of ZEB1 in H1975, A549 and PANC-1 cells; and the down-regulation 
of E-cadherin in H827, H1975 and PAC-1 cells; although some of these changes 
were only slight. These results suggest that monensin has a partial inhibitory 
effect on TGF-β-induced EMT. We then examined the combinatorial effect on cell 
growth of osimertinib and monensin in cell viability assays to confirm whether 
acquired resistance to EGFR-TKI thorough TGF-β-induced EMT could be 
overcome by combination therapy with monensin. Treatment with monensin 
alone showed some effect on cell growth, with IC50 values of 1.06 μM for HCC827 
cells, 1.76 μM for H1975 cells, 0.74 μM for A549 cells, and 0.29 μM for PANC-1 
cells (Fig. 3B), and the addition of monensin restored the growth inhibitory effect 
of osimertinib in the two EGFR-mutant NSCLC cell lines with TGF-β-induced EMT 
(Fig. 3C). To evaluate drug-induced apoptosis, cells were treated in the presence 
or absence of monensin and/or TGF-β for 72 hours, and the expression of the 
apoptosis marker cleaved-PARP was analyzed using western blotting. The 
expression of cleaved-PARP was suppressed by TGF-β treatment, while the 
addition of monensin restored the induction of apoptosis by osimertinib (Fig. 3D). 
Taken together, these results showed that the addition of monensin could restore 






Acquired drug resistance against molecularly targeted therapy has been 
intensely studied especially in EGFR-mutant NSCLCs, and the most prominent 
mechanism of the secondary EGFR T790M mutation can be targeted 
successfully using third-generation drugs such as osimertinib [16]. However, the 
long-term clinical benefits remain unsatisfactory because a diversity of other 
mechanisms also contribute to drug resistance. One of the key mechanisms of 
resistance is the acquisition of an EMT signature, which is involved in not only 
molecularly targeted drugs, but also chemotherapy with cytotoxic drugs or 
radiation therapy in diverse cancer types [17-19]. Therefore, a novel therapeutic 
strategy to overcome this resistance is a promising approach to improving 
outcomes. In the present study, we used a bioinformatics approach using C-MAP 
analysis to search for drugs with the potential to revert the EMT, and we identified 
monensin as a candidate anti-EMT drug. In vitro validation analyses 
demonstrated that monensin inhibited EMT conversion and improved drug 
response.  
Monensin is a polyether ionophore antibiotic that is known to be a promoter of 
muscle growth in veterinary medicine. Monensin has been added to cattle and 
poultry feed for years and has a positive safety profile [11]. Prior to this study, 
monensin had been reported to exhibit an anti-cancer effect by inhibiting cell 
proliferation, cell cycle progression and cell migration and by inducing cell 
apoptosis in diverse cancer types, such as lung cancer, pancreatic cancer, renal 
cancer, colon cancer, prostate cancer, and ovarian cancer [20-24]. Of note, 
malignant cells were 20-fold more sensitive to monensin than normal cells, 
indicating that monensin could be a cancer-specific therapeutic drug [22]. 
Mechanically, monensin has been shown to induce a Golgi apparatus stress 
response, mitochondrial damage, and oxidative stress, initiating signaling 
pathways to trigger apoptosis through the up-regulation of Bax, caspase-3 and 
caspase-8 [22, 24, 25]. Monensin has also been reported to target multiple 
signaling pathways, such as EGFR, Hedgehog, Wnt, CDK6, cyclin D1, and cyclin 
A, as well as multiple transcript factors, including E2F/DP1, STAT1/2, NFκB, AP-
1 and Elk-1/SRF [20, 21, 23, 24, 26]. Of note, Vanneste et al. conducted a 
systematic high throughput screening for compounds with anti-EMT activity and 
demonstrated that EMT-like cells exhibited a greater uptake of monensin 
compared with cells with epithelial features, leading to a selective cytotoxic effect 
on an EMT phenotype [25]. However, our data using an isogenic NSCLC cell line 
model showed no relationships between the sensitivity to monensin and the EMT 
status (Supplementary Figure 1A and 1B). Specifically, we established a distinct 
isogenic cell model using HCC827 cells that had been chronically exposed to 
osimertinib, and the resistant cells acquired an EMT phenotype (Supplementary 
Figure 1A), leading to EMT-mediated drug resistance to EGFR-TKI and cytotoxic 
reagents [27]. In terms of sensitivity to monensin, unexpectedly, no significant 
differences were observed between the parental cells and the resistant cells 
despite their different EMT statuses (Supplementary Figure 1B). Furthermore, 
monensin treatment did not restore the epithelial phenotype (Supplementary 
Figure 2A) or the sensitivity to EGFR-TKI in the resistant cells with EMT 
conversion (Supplementary Figure 2B). Considering these findings, monensin 
might not have a direct effect on the EMT signatures in our resistant cells, and 
the inhibition of EMT conversion might be obtained through the suppression of 
some EMT-facilitating factors, including TGF-β. Furthermore, its effect likely 
differs depending on the cancer type. Further study is warranted to elucidate this 
intriguing biological mechanism.  
In the 1990s, the calcium channel blocker verapamil was tested in a clinical trial 
as a chemosensitizer to reverse drug resistance by inhibiting a drug efflux pump, 
which is the one of the key functions of EMT-mediated resistance. However, 
because of the dose-limiting toxicity, verapamil did not show any clear evidence 
of a beneficial effect on cytotoxic chemotherapy reagents [1]. Monensin has been 
approved by the FDA for veterinary use and has been shown to have a positive 
biosafety profile in veterinary medicine. In previous studies, the antitumor activity 
of monensin was demonstrated in an in vivo model, and no significant adverse 
effects were seen even at a much higher dose of monensin than the 100-nM dose 
used in the present study[20, 23]. Nonetheless, in attempting to translate our 
findings clinically, careful assessment of any possible toxic effects of long-term 
use in humans is warranted prior to repositioning monensin as a combinatory 
therapy with standard antitumor reagents. 
In conclusion, the current study demonstrated the possible utility of monensin as 
a prophylactic when co-administered with antitumor reagents to prevent the 
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Fig. 1. Identification of reagents with the potential to reverse the EMT using C-
MAP analysis. (A) Classification of 28 NSCLC cell lines according to their EMT 
status. (B) Representative GSEA enrichment plots for the Epithelial 
Mesenchymal Transition gene sets for 28 NSCLC cell lines. (C) Representative 
results of Kolmogorov-Smirnov scanning showing an enrichment of outcome-
associated probe sets for the 4th ranked monensin, indicating the up-regulation 
of 87 epithelial-like probes and the down-regulation of 52 mesenchymal-like 
probes. (D) Summaries of all instances of monensin. The barview shows the 
instances of monensin in a total of 6100 instances. 
 
Fig. 2. Establishment of TGF-β-induced EMT models using three NSCLC cell 
lines and one pancreatic cancer cell line. (A) Cells were treated with TGF-β (2 
ng/mL) for 72 hours and then subjected to immunoblotting. The relative band 
intensity was quantified using a densitometric analysis with ImageJ software. (B) 
PANC-1 and A549 cells were treated with TGF-β (2 ng/mL) for 5 days; 
representative microscopy images are shown. The scale bar represents 100 nm. 
(C) HCC827 and H1975 cells were pretreated with TGF-β (2 ng/mL) for 24 hours 
and were then subsequently treated with osimertinib for 96 hours. Cell viability 
was determined using CellTiter 96 Aqueous bromide dye. Each experiment was 
assayed in eight replicate determinations, and the data are representative of 
three independent experiments (mean ± SE). 
 
Fig. 3. Monensin restores the growth inhibitory effect of osimertinib through the 
prevention of TGF-β-induced EMT. (A) Cells were cultured in the presence or 
absence of monensin (100 nM) and/or TGF-β (2 ng/mL) for 72 hours, then 
subjected to immunoblotting. The relative band intensity was quantified using a 
densitometric analysis with ImageJ software. (B) Cells were treated with 
monensin for 96 hours. Cell viability was determined using CellTiter 96 aqueous 
bromide dye. Each experiment was assayed in eight replicate determinations, 
and the data are representative of three independent experiments (mean ± SE). 
(C) HCC827 and H1975 cells were pretreated with TGF-β (2 ng/mL) in the 
presence or absence of monensin (100 nM) for 24 hours, then subsequently 
treated with osimertinib for 96 hours. Cell viability was determined using CellTiter 
96 Aqueous bromide dye. Each experiment was assayed in eight replicate 
determinations, and data are representative of three independent experiments 
(mean ± SE). (D) HCC827 and H1975 cells were pretreated with TGF-β (2 ng/mL) 
in the presence or absence of monensin (100 nM) for 24 hours, then followed by 







Table 1 Permuted results of C-MAP analysis (top 20 list of reagent) 
 
Rank cmap name n Enrichment P value 
1 thioridazine 182 0.475 0.0001 
2 monensin 20 0.731 0.00101 
3 sulfamonomethoxine 12 0.806 0.00265 
4 mebeverine 6 0.801 0.00298 
5 perphenazine 4 0.726 0.00348 
6 zuclopenthixol 4 0.782 0.0042 
7 oxamniquine 4 0.782 0.00422 
8 gibberellic acid 5 0.764 0.00585 
9 phentolamine 4 0.599 0.00605 
10 meclofenamic acid 4 0.695 0.00655 
 
 
 
 
 
